Retatrutide (only Available in injectable) (GLP-1/GIP/Glucagon Receptor Triple Agonist) Retatrutide is a synthetic peptide currently under investigation for its potent effects on metabolic regulation. It functions as a triple agonist at the GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors, making it a unique and powerful tool for metabolic research. Preclinical and early clinical studies have shown that Retatrutide may influence multiple metabolic pathways simultaneously, including: Appetite suppression through enhanced satiety signaling Increased energy expenditure via glucagon receptor activation Improved glucose homeostasis by enhancing insulin secretion and sensitivity Significant reductions in body weight and fat mass in experimental models Due to its multi-receptor activity, Retatrutide is being explored as a next-generation candidate in the study of obesity, type 2 diabetes, and related metabolic disorders. For Research Use Only. Not for Human Consumption. This product is strictly intended for laboratory research purposes and is not approved for human or veterinary use.